Therapeutic Agents

ANBITION has discovered and is developing up to the clinical phases several peptides having
anti-angiogenic properties.
ANBITION’s pipeline also includes the development of selective delivery systems to improve the therapeutic index of drugs for oncology applications.
Such delivery systems are based on human albumin nanoparticle carriers (NP-HSA) loaded with drugs and decorated with targeting agents like antibody fragments and bioactive peptides.